GlassScriptPhysician profile
Peggy B Liao
NPI 1699799379
$5,064.74
in general payments reported to CMS, 2019-2025
26 companies · $839 in 2025
The $839 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $465 · 2020: $566 · 2021: $813 · 2022: $649 · 2023: $840 · 2024: $892 · 2025: $839.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,377 · Education: $195.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,376.57 |
| Education | $195.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $779.35 | 2019-2025 | |
| Genzyme Corporation | $434.72 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $433.74 | 2019-2025 | Ilumya |
| Janssen Biotech, INC. | $426.04 | 2019-2025 | Tremfya, Simponi Aria, Remicade |
| Pfizer INC. | $320.81 | 2019-2023 | |
| Regeneron Healthcare Solutions, INC. | $300.70 | 2019-2025 | Dupixent |
| Amgen INC. | $252.43 | 2019-2025 | Otezla, Otezla, Tepezza |
| Galderma Laboratories, L.P. | $242.15 | 2019-2025 | Nemluvio |
| Lilly USA, LLC | $234.84 | 2019-2024 | Taltz, Olumiant, Zepbound |
| E.R. Squibb & Sons, L.L.C. | $222.71 | 2022-2024 | Sotyktu |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $207.43 | 2019-2024 | Jublia, Cabtreo |
| Ucb, INC. | $196.69 | 2021-2025 | Bimzelx |
| Leo Pharma INC. | $174.25 | 2019-2025 | Adbry, Anzupgo |
| Novartis Pharmaceuticals Corporation | $149.56 | 2019-2025 | |
| Incyte Corporation | $143.52 | 2022-2025 | Opzelura |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $102.35 | 2019-2025 | Klisyri |
| Arcutis Biotherapeutics, INC. | $89.66 | 2023-2025 | Zoryve |
| Sanofi-Aventis U.S. LLC | $79.99 | 2025 | |
| Organon LLC | $69.15 | 2025 | Vtama |
| Dermira, INC. | $47.73 | 2019-2020 | |
| Journey Medical Corporation | $37.42 | 2019-2025 | |
| Sandoz INC. | $32.55 | 2023 | Hyrimoz |
| Epi Health, LLC | $31.20 | 2019-2021 | |
| Celgene Corporation | $30.89 | 2019 | |
| Allergan, INC. | $15.50 | 2019 | |
| Prugen, INC. Pharmaceuticals | $9.36 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peggy Liao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.